Strand Therapeutics
A Co-op position at Strand Therapeutics supporting analytical development in mRNA and LNP technologies. The role involves executing experiments, analyzing data, and supporting process development in a fast-paced biotech environment.
Headquarters
Boston, Massachusetts, United States
Company Size
51-200 employees
Founded
2017
Strand Therapeutics is a clinical-stage biotechnology company developing programmable mRNA therapeutics for solid tumors, blood cancers, and autoimmune diseases. The company's platform addresses core challenges in genetic medicine—targeting, safety, and potency—through proprietary technologies including SignalPath LNPs for tissue-specific delivery, SignalLock RNA for microRNA-based mRNA encryption, and SignalScript RNA for enhanced potency and durability. Its pipeline includes STX-001 for solid tumors, STX-003 for systemic tumor delivery, and STX-005, a pioneering in vivo CAR-T approach for autoimmune diseases and blood cancers.
Opinion | The U.S. can’t afford to offshore clinical trials to China
1 week ago
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline
Aug 7, 2025
Investors back Strand Therapeutics’ targeted cytokine therapies
Aug 21, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Strand Therapeutics.
18% below the average for this role
Strand Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Dec 16, 2025